{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.48","upperLimit":"1.0","value":"0.71"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"Kaplan-Meier method, duration of response probability in patients with partial response or better. Events defined as confirmed progression or death from any cause","dispersionType":"90% Confidence Interval","groups":[{"description":"* A treatment cycle is defined as 28 consecutive days.\n* Participants will receive 6 cycles of induction therapy followed by 6 cycles of maintenance therapy with lower doses of lenalidomide and no dexamethasone for a total of 12 months.\n\nNivolumab: Intravenous, predetermined dosage, Days 1 and 15 during cycles 1-12 and\n\nLenalidomide: Oral, predetermined dosage, Days 1-21 of cycle 1-12\n\nDexamethasone: Oral, Days 1, 8, 15 of cycle 1-6","id":"OG000","title":"Nivolumab, Lenalidomide, Dexamethasone"}],"paramType":"NUMBER","populationDescription":"7 of 8 patients achieved a confirmed objective response and are included in duration of response analysis","reportingStatus":"POSTED","timeFrame":"time from objective response to disease progression or death, or date last known progression-free and alive for those who have not progressed or died, up to 24 months post initiation of therapy.","title":"Duration of Response Probability at 2-years","type":"SECONDARY","unitOfMeasure":"probability"}